Xenetic Biosciences, Inc. appointed James F. Parslow as Interim CEO and made changes to his employment agreement, including an increase in salary and stock option grant. The company also entered into separation agreements with former CEO and Chief Scientific Officer, providing severance payments and accelerated vesting of stock options.